P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease

计划入组 8 人 · 首次发布于 2024 年 7 月 5 日

Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1

计划入组 2 人 · 首次发布于 2019 年 3 月 19 日

Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease

计划入组 66 人 · 首次发布于 2021 年 7 月 12 日

Hydroxypropyl betadex

C₆₀H₁₀₆O₄₀

Piroxicam/β-Cyclodextrin

Trappsol Cyclo

MEREO BIOPHARMA 2 LIMITED

United Kingdom

UpJohn US 2 LLC

United States

RIVER 2 RENAL CORP.

United States

FDA Grants Breakthrough Therapy Designation to Adrabetadex for Infantile-Onset Niemann-Pick Disease Type C

MTX110 Shows Promise in Recurrent Glioblastoma: Phase 1 Data

FDA Authorizes Emergency Compassionate Use of VAR 200 for Ultra-Rare ApoCII Amyloidosis